ClinicalTrials.gg
Not yet recruitingNCT07950475Updated Nov 20, 2026

Methodological Validation of Antera 3D for Quantitative Assessment of Atrophic Scars

An observational study in Atrophic Scar, sponsored by CellinCells. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by CellinCells · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
28
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Cicatrix with a site in Korea, Republic of — 4 open to participants now, 5 under way, none of them phase 3. Cicatrix · Korea, Republic of.

Started
2026
with 3 others
Observational
4 of 20
3 open now
Registered
20th of 20
by date
Lead sponsor
6 of 20
CellinCells

Among the 20 studies in Cicatrix with a site in Korea, Republic of, this one is one of 4 that started in 2026, is one of 4 observational ones, and was the 20th registered.

Cicatrix

616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.

Browse Cicatrix studies →

Open to participants now

4 of the 20 studies in Cicatrix with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Cicatrix with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical study aims to establish standardised image acquisition and analysis methods using Antera 3D for the quantitative assessment of atrophic scars.

03

Conditions studied

  • Atrophic Scar

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals with Atroptic Scars

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 19 years or older
  • Participants wit atrophic acars or in the temporal regions of tha face
  • Participants with atrophic scars on the cheeks or in the temporal regions of the face for whom a circular region of interest (ROI) with a diameter of 2 cm can be defined for analysis (i.e., the ROI contains atrophic scars).
  • Participants who voluntarily provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Participants with infectious skin diseases or other forms of dermatitis affecting the face.
  • Participants with serious acute, chronic, or progressive diseases that may preclude participation in the study.
  • Participants who are considered unsuitable for participation in the study, as determined by the Investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
28 participants (estimated)
Patient registry
No

Groups and cohorts

  • A Single Group

    Participant with Atrophic Scar

06

What researchers measure

Primary outcomes

  1. Test-retest repeatability of Depression Volume Measured Using Antera 3D

    Test-retest repeatability of depression volume will be evaluated using the intraclass correlation coefficient (ICC) based on three independent image acquisitions of the same target region of interest (ROI) in each participant, with repositioning between acquisitions. Depression volume will be determined using Antera 3D image analysis software.

    Time frame: At Visit 1 (Day 1)

Secondary outcomes

  1. Test-Retest Repeatability of Depression Area Measured Using Antera 3D

    Test-retest repeatability of depression area will be evaluated using the intraclass correlation coefficient (ICC) based on three independent image acquisitions of the same target region of interest (ROI) in each participant, with repositioning between acquisitions. Depression area will be determined using Antera 3D image analysis software.

    Time frame: At Visit 1 (Day 1)

  2. Test-Retest Repeatability of Maximum Depth Measured Using Antera 3D

    Test-retest repeatability of maximum depth will be evaluated using the intraclass correlation coefficient (ICC) based on three independent image acquisitions of the same target region of interest (ROI) in each participant, with repositioning between acquisitions. Maximum depth will be determined using Antera 3D image analysis software.

    Time frame: At Visit 1 (Day 1)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 23 observational studies under Cicatrix, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 7. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 20, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Feb 26, 2027
CompletionEst.
May 30, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950475
Lead sponsor
CellinCells
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Feb 26, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

HyeJung Park
Contact
hjpark@cillincills.com
+82-70-44699115

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion